Craft

PhaseBio Pharmaceuticals

Stock Price

$0

2023-01-04

Market Capitalization

$3.4 M

2023-01-04

Revenue

$10.8 M

FY, 2021

PhaseBio Pharmaceuticals Summary

Company Summary

Overview
PhaseBio Pharmaceuticals is a biopharmaceutical company committed to developing new and improved drugs, with an initial focus on endocrine and metabolic disorders and cardiovascular disease. The Company uses its proprietary recombinant biopolymers called elastin-like polypeptides (ELPs) to improve the stability, bioavailability, activity and ease of administration of proteins and peptides, with the goal of achieving greater potency, fewer side effects and better patient compliance.
Type
Public
Status
Active
Founded
2002
HQ
Malvern, PA, US | view all locations
Website
http://www.phasebio.com
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Jonathan Mow

    Jonathan Mow, Chief Executive Officer

    • Clay Thorp

      Clay Thorp, Chairman

      • Glen Burkhardt

        Glen Burkhardt, Vice President of Human Resources

        • John Lee

          John Lee, Chief Medical Officer

          LocationsView all

          1 location detected

          • Malvern, PA HQ

            United States

            1 Great Valley Pkwy #30

          PhaseBio Pharmaceuticals Financials

          Summary Financials

          Revenue (Q2, 2022)
          $208.0K
          Net income (Q2, 2022)
          ($16.7M)
          Cash (Q2, 2022)
          $7.8M
          EBIT (Q2, 2022)
          ($25.3M)
          Enterprise value
          ($359.9K)

          Blogs

          Footer menu